Navigation Links
Investigational PARP inhibitor promising in BRCA-related cancers
Date:10/22/2013

BOSTON An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

When there is damage to DNA in human cells, two proteins, PARP 1 and 2, recruit proteins that can repair the damage associated with loss of BRCA proteins. Mutations in BRCA genes often result in inefficient repair of damaged DNA, which increases the risk for developing certain cancers, including cancers of the breast and ovary. Inhibiting PARP, therefore, prevents the repair of damaged DNA, leading to cell death. While some PARP inhibitors have been tested in various settings, none are approved to date.

"BMN 673 is the most potent PARP inhibitor in clinical development and has optimized pharmaceutical properties: it is well absorbed orally, has substantial single-agent antitumor activity, and has a long half-life allowing once-daily dosing," said Zev A. Wainberg, M.D., assistant professor of medicine at the Jonsson Comprehensive Cancer Center of the University of California Los Angeles School of Medicine. "The clinical data to date are promising and compare favorably with results from clinical trials with other PARP inhibitors. We observed high objective and clinical benefit response rates in BRCA-related breast and ovarian cancers at low, oral, once-daily doses.

"Based on this phase I study, we feel there's a good chance that patients with BRCA-related cancers who meet the study eligibility criteria will have disease control for a meaningful period of time with relatively few side effects. However, randomized trials are necessary to demonstrate whether this will translate into improvements in progression-free and overall survival relative to currently available therapies," said Wainberg.

He and colleagues conducted a phase I trial to evaluate the safety and efficacy of BMN 673 in a two-stage dose escalation/expansion study. So far, they have recruited 39 and 41 patients to the escalation phase and expansion phase, respectively. Patients were 18-82 years old, and they had undergone one to 13 prior therapies.

Fifty participants18 with breast cancer, 28 with ovarian cancer, three with pancreatic cancer, and one with prostate cancerhad BRCA mutations in their tumors. Wainberg reported that to date, among the patients with BRCA mutations in their tumors, 44 percent of those with ovarian cancer and 44 percent with breast cancer had an objective response. Overall, 82 percent of the ovarian cancer patients and 72 percent of the breast cancer patients had clinical benefit (measured by imaging data and/or CA 125 levels for ovarian cancers and by imaging data for breast cancers).

In patients being treated at the 1 mg dose recommended for future trials, 50 percent of the breast cancer patients with BRCA mutations had an objective response and 86 percent had clinical benefit. Of the three patients with pancreatic cancer, two have had stable disease.

Fewer than 20 percent of the patients had grade 3 adverse events including fatigue, anemia, neutropenia, and thrombocytopenia, and one patient had a grade 4 toxicity.

Given the high objective and clinical benefit response rates in breast cancer patients, the investigators have recently initiated a phase 3 trial in metastatic breast cancer with BRCA mutations, according to Wainberg.

Among those with BRCA-unrelated cancers recruited to the phase 1 trial, one of the seven currently evaluable patients with small-cell lung cancer (SCLC) has responded, according to Wainberg. This patient, whose tumor metastasized extensively, has an ongoing partial response, he explained. "A solid partial response in a patient with SCLC provides some optimism about finding indications other than BRCA-related tumors that will benefit from treatment with BMN 673," he said.


'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
2. Investigational malaria vaccine found safe and protective
3. Method patent issued for investigational new class of pain medication
4. Investigational agent targets gene signaling pathways to improve response for patients with CLL
5. Prostacyclin analogs and PDE 5 inhibitors synergistically stimulate ATP release from human RBCs
6. Dr. Gary McClain of JustGotDiagnosed.com Speaking at Inhibitor Family Camp
7. Possible predictive biomarker for patients who may respond to autophagy inhibitors
8. Agios research demonstrates the effects of mutant IDH1 and IDH2 inhibitors in primary tumor models
9. Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors
10. BRAF inhibitor treatment causes melanoma cells to shift how they produce energy
11. Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2019)... ... , ... We are pleased to honor thirteen U.S. ... Rising Star ! Each year, Texas Monthly asks doctors across the state ... care. The Super Doctors research team then investigates independently. Candidates are evaluated based ...
(Date:7/17/2019)... , ... July 17, 2019 , ... ... leader offering fresh, insightful, honest perspectives on today’s issues affecting humanity at practical ... 12 p.m. PST on Saturday, July 20, 2019. , Guruji Mahendra Trivedi ...
(Date:7/17/2019)... ... July 17, 2019 , ... Dynamic Healthcare Systems, ... Advantage, Medicaid, and Marketplace programs is pleased to announce the introduction of an ... (EHR) integration at the point of care to providers and provider groups ...
(Date:7/17/2019)... Minn. (PRWEB) , ... July 17, 2019 , ... ... assist healthcare providers working with the ICD-10 coding set, is launching an exclusive ... Education Units (CEUs) at no additional charge, officials announced this week. , ...
(Date:7/17/2019)... ... July 17, 2019 , ... People considering surrogacy usually have an ... Parents’ story differs , but, in addition to creating a family, they have the ... more and more Intended Parents are electing to have a child through the surrogacy ...
Breaking Medicine News(10 mins):
(Date:7/18/2019)... ... July 18, 2019 , ... Fresh blueberries are now ... Berry Collection of homegrown edible berry bushes. , These ornamental berry shrubs, which ... fruit to any garden or on the patio in containers, not out of sight ...
(Date:7/17/2019)... ... July 17, 2019 , ... Highmark Health, Allegheny Health Network (AHN) and ... the region to announce plans for what will be one of the largest health ... State Avenue and adjacent to the Montour Trail, the complex is being developed by ...
(Date:7/17/2019)... ... , ... Eargo the direct-to-consumer health tech company destigmatizing hearing loss ... executive hires: CFO Adam Laponis (from Tesla, Inc.), CMO Shiv Singh (from Visa, Inc., ... , The new hires come on the heels of Eargo’s $52 million ...
Breaking Medicine Technology: